⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Impact of the Oral Orexin Receptor 2 Agonist TAK-994 on Sustained Attention in Patients with Narcolepsy Type 1: Exploratory Results from a Phase 2 Study (P11-9.012)

Yves Dauvilliers Giuseppe Plazzi Elena Koundourakis Yeting Du Christian von Hehn Dmitri Volfson Robert D. Latzman Brian Harel

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate the effect of TAK-994 on sustained attention and vigilance in patients with narcolepsy type 1 (NT1).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dauvilliers et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677f25 https://doi.org/10.1212/wnl.0000000000205786

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 12025 · 1 citations
2The First Light: Efficacy and Safety of a Multi-dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One (S3.010)Original Research · 2026
3TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse modelsOriginal Research · 2024 · 20 citations
4The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One (P6-14.001)Original Research · 2026
5C21-01 Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1: Results From the Phase 3 Radiant Light StudyBlinded Clinical Trial · 2026